If Telvantis with AmeriCrews delivers $267M in revenue and $5.3M in net income, the numbers break out very differently depending on where you place them. On NASDAQ revenue-based multiples, the valuation falls in the $500m to $1.1B range, translating to roughly $0.06 to $0.13 per share. On earnings-based multiples, the outcome is much lighter, closer to $100M, or about a penny a share. Shift the same model to the OTC and the weight comes down even further. That’s the trade-off, an IPO on NASDAQ is expensive and time-consuming, while the reverse merger path through OTC is quicker, but it carries the caveats of limited multipliers and no institutional support.
Will percentage gains be seen? Surely. Just keep expectations grounded.
Bullish
Market Data 
Markets 
AI
